Table 4.
Multivariate analyses for tumor recurrence and tumor‐related death in all patients with invasive ductal carcinoma (IDC) who received neoadjuvant chemotherapy
| Factors | Tumor recurrence | Tumor‐related death | ||||
|---|---|---|---|---|---|---|
| HRs | 95% CI | P‐values | HRs | 95% CI | P‐values | |
| Model 1 | ||||||
| Clinical invasive tumor size (mm) before neoadjuvant chemotherapy | ||||||
| >20 to ≤50 | Referent | Referent | ||||
| >50 | 2.2 | 1.1–4.4 | 0.034 | – | – | |
| Grading system for lymph vessel tumor emboli assessed using biopsy materials obtained before neoadjuvant chemotherapy | ||||||
| Grade 0 | Referent | Referent | ||||
| Grade 1 | – | – | 0.7 | 0.03–14.2 | 0.796 | |
| Grade 2 | – | – | 5.9 | 1.3–27.9 | 0.025 | |
| Fibrotic focus assessed using biopsy materials obtained before neoadjuvant chemotherapy | ||||||
| Absent | Referent | Referent | ||||
| Present | – | – | 6.2 | 1.9–19.6 | 0.002 | |
| Tumor necrosis assessed using surgical materials obtained after neoadjuvant chemotherapy | ||||||
| Absent | Referent | Referent | ||||
| Present | 2.9 | 1.1–8.0 | 0.034 | 1.2 | 0.2–9.1 | 0.868 |
| No. of mitotic figures in nodal metastatic tumors assessed using surgical materials obtained after neoadjuvant chemotherapy | ||||||
| N0 and ≤5 | Referent | Referent | ||||
| >5 | 4.5 | 1.7–11.9 | 0.003 | 7.5 | 1.7–31.5 | 0.006 |
| Nodes with extranodal invasion assessed using surgical materials obtained after neoadjuvant chemotherapy | ||||||
| N0 and absent | Referent | Referent | ||||
| Present | 4.8 | 2.3–10.6 | <0.001 | 5.0 | 1.7–14.7 | 0.003 |
| Nodal metastatic tumor stroma assessed using surgical materials obtained after neoadjuvant chemotherapy | ||||||
| N0 and none | Referent | Referent | ||||
| Mild | 0.7 | 0.1–5.3 | 0.719 | 1.1 | 0.04–28.3 | 0.967 |
| Moderate | 1.3 | 0.2–7.8 | 0.771 | 4.5 | 0.3–76.9 | 0.302 |
| Severe | 3.9 | 1.6–9.2 | 0.002 | 7.6 | 0.3–183.9 | 0.214 |
| Model 2 | ||||||
| Grading system for lymph vessel tumor emboli assessed using surgical materials obtained after neoadjuvant chemotherapy | ||||||
| Grade 0 | Referent | Referent | ||||
| Grade 1 | 3.2 | 1.2–8.6 | 0.020 | 0.2 | 0.01–3.8 | 0.302 |
| Grade 2 | 9.5 | 3.3–27.3 | <0.001 | 5.9 | 1.9–18.8 | 0.002 |
| Grade 3 | 5.5 | 1.7–17.4 | 0.004 | 5.3 | 0.5–61.6 | 0.183 |
| Tumor necrosis assessed using surgical materials obtained after neoadjuvant chemotherapy | ||||||
| Absent | Referent | Referent | ||||
| Present | 3.1 | 1.1–8.8 | 0.038 | 2.4 | 0.8–13.3 | 0.300 |
| No. of mitotic figures in nodal metastatic tumors assessed using surgical materials obtained after neoadjuvant chemotherapy | ||||||
| N0 and ≤5 | Referent | Referent | ||||
| >5 | 3.7 | 1.2–11.7 | 0.027 | 12.6 | 3.2–48.5 | <0.001 |
| Nodal metastatic tumor stroma assessed using surgical materials obtained after neoadjuvant chemotherapy | ||||||
| N0 and none | Referent | Referent | ||||
| Mild | 0.4 | 0.05–3.1 | 0.366 | 0.2 | 0.01–6.9 | 0.395 |
| Moderate | 2.9 | 1.2–7.1 | 0.017 | 1.3 | 0.1–17.9 | 0.856 |
| Severe | 10.0 | 3.3–20.9 | <0.001 | 3.5 | 1.1–10.8 | 0.034 |
–/–, not significant in univariate analysis; CI, confidence interval; HR, hazard rate; N0, no nodal metastasis.